Cardio Diagnostics Holdings, Inc. announced that at the annual meeting of stockholders held on December 18, 2023, elected Paul F. Burton, J.D., MBA as Director. The company announced on December 21, 2023, the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee.

Mr. Burton is the Managing Partner at 2Flo Ventures. He is also the CEO of Akan Biosciences. Mr. Burton brings over 20 years of experience in medical technology innovation, corporate finance, and shaping the strategy and operations of growth-stage companies.

Before 2Flo Ventures, Mr. Burton was CEO of several venture-backed companies developing novel therapeutics. He began his career in investment banking at Citigroup. Mr. Burton holds J.D. and MBA degrees from the University of Illinois Urbana-Champaign.

Over the years, he has helped raise more than $6 billion for more than 20 companies. He has particular expertise in FDA navigation for companies building novel therapeutics and medical technologies.